mGluR2 positive allosteric modulators: a patent review (2009 – present)

Bibliography

• Niswender CM, Conn JP. Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu Rev Pharmacol Toxicol 2010;50:295-322
   PubMed Web of Science ®Google Scholar
• Pilc A, Chaki S, Nowak G, Witkin JM. Mood disorders: regulation by metabotropic glutamate receptors. Biochem Pharmacol 2008;75:997-1006
   PubMed Web of Science ®Google Scholar
• Luscher C, Huber KM. Group 1 mGluR-dependent synaptic long-term depression: mechanisms and implications for circuitry and disease. Neuron 2010;65:445-59
   PubMed Web of Science ®Google Scholar
• Vinson PN, Conn PJ. Metabotropic glutamate receptors as therapeutic targets for schizophrenia. Neuropharmacology 2012;62:1461-72
   PubMed Web of Science ®Google Scholar
• Chiechio S, Nicoletti F. Metabotropic glutamate receptors and the control of chronic pain. Curr Opin Pharmacol 2012;12:28-34
   PubMed Web of Science ®Google Scholar
• Foster OM. Metabotropic glutamate receptor ligands as potential therapeutics for addiction. Curr Drug Abuse Rev 2009;2:83-98
   PubMedGoogle Scholar
• Johnson KA, Conn PJ, Niswender CM. Glutamate receptors as therapeutic targets for Parkinson's disease. CNS Neurol Disord Drug Targets 2009;8:475-91
   PubMed Web of Science ®Google Scholar
• Watkins JC. L-glutamate as a central neurotransmitter: looking back. Biochem Soc Trans 2000;28:297-310
   PubMed Web of Science ®Google Scholar
• Kew JNC, Kemp JA. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology (Berl) 2005;179:4-29
   PubMed Web of Science ®Google Scholar
• Huang S, Cao J, Jiang M, Interdomain movements in metabotropic glutamate receptor activation. Proc Natl Acad Sci USA 2011;108:15480-5
   PubMed Web of Science ®Google Scholar
• Pin JP, Galvez T, Prezeau L. Evolution, structure, and activation mechanism of family 3/C G-protein-coupled receptors. Pharmacol Ther 2003;98:325-54
   PubMed Web of Science ®Google Scholar
• Brauner-Osborne H, Wellendorph P, Jensen AA. Structure, pharmacology and therapeutic prospects of family C G-protein coupled receptors. Curr Drug Targets 2007;8:169-84
   PubMed Web of Science ®Google Scholar
• Cartmell J, Schoepp DD. Regulation of neurotransmitter release by metabotropic glutamate receptors. J Neurochem 2000;75:889-907
   PubMed Web of Science ®Google Scholar
• Ohishi H, Shigemoto R, Nakanishi S, Mizuno N. Distribution of the messenger RNA for metabotropic glutamate receptor, mGlu2, in the central nervous system of the rat. Neuroscience 1993;53:1009-18
   PubMed Web of Science ®Google Scholar
• Richards G, Messer J, Malherbe P, Distribution and abundance of metabotropic glutamate receptor subtype 2 in rat brain revealed by [3H]LY354740 binding in vitro and quantitative radioautography: correlation with the sites of synthesis, expression, and agonist stimulation of [35S]GTPS binding. J Comp Neurology 2005;487:15-27
   PubMed Web of Science ®Google Scholar
• Gu G, Lorrain DS, Wei H, Distribution of metabotropic glutamate 2 and 3 receptors in the rat forebrain: implication in emotional responses and central disinhibition. Brain Res 2008;1197:47-62
   PubMed Web of Science ®Google Scholar
• Ghose S, Gleason KA, Potts BW, Differential expression of metabotropic glutamate receptors 2 and 3 in schizophrenia: a mechanism for antipsychotic drug action? Am J Psychiatry 2009;166:812-20
   PubMed Web of Science ®Google Scholar
• Shigeyuki C, Hirohiko H. Targeting of metabotropic glutamate receptors for the treatment of schizophrenia. Curr Pharm Des 2011;17:94-102
   PubMed Web of Science ®Google Scholar
• Monn JA, Valli MJ, Massey SM, Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. J Med Chem 1997;40:528-37
   PubMed Web of Science ®Google Scholar
• Swanson CJ, Bures M, Johson MP, Glutamate Receptors as novel targets for anxiety and stress disorders. Nat Rev Drug Discov 2005;4:131-44
   PubMed Web of Science ®Google Scholar
• Fell MJ, McKinzie DL, Monn JA, Svensson KA. Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia. Neuropharmacology 2012;62:1473-83
   PubMed Web of Science ®Google Scholar
• Levine L, Gaydos B, Sheehan D, The mGlu2/3 receptor agonist, LY354740, reduces panic anxiety induced by a CO2 challenge in patients diagnosed with panic disorder. Neuropharmacology 2002;43:294
   Web of Science ®Google Scholar
• Dunayevich E, Erickson J, Levine L, Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology 2008;33:1603-10
   PubMed Web of Science ®Google Scholar
• Patil ST, Zhang L, Martenyi F, Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 2007;13:1102-7
   PubMed Web of Science ®Google Scholar
• Fell MJ, McKinzie DL, Monn JA, Svensson KA. Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia. Neuropharrmacology 2012;62:1473-83
   PubMed Web of Science ®Google Scholar
• Lilly Stops Phase III development of pomaglumetad methionil for the treatment of Schizophrenia based on efficacy results. Eli Lilly and Co. 2012. Available from: https://investor.lilly.com/releaseDetail.cfm?ReleaseID=703018
   Google Scholar
• Iacovelli L, Molinaro G, Battaglia G, Regulation of group II metabotropic glutamate receptors by G protein-coupled receptor kinases: mGlu2 receptors are resistant to homologous desensitization. Mol Pharmacol 2009;75:991-1003
   PubMed Web of Science ®Google Scholar
• Lennon SM, Rivero G, Matharu A, Metabotropic glutamate receptor mGlu2 is resistant to homologous agonist-induced desensitization but undergoes protein kinase C-mediated heterologous desensitization. Eur J Pharmacol 2010;649:29-37
   PubMed Web of Science ®Google Scholar
• Pin JP, Parmentier M-L, Prezeau L. Positive allosteric modulators for -aminobutyric acidB receptors open new routes for the development of drugs targeting family 3 G-protein-coupled receptors. Mol Pharmacol 2001;60:881-4
   PubMed Web of Science ®Google Scholar
• Gjoni T, Urwyler S. Receptor activation involving positive allosteric modulation, unlike full agonism, does not result in GABAB receptor desensitization. Neuropharmacology 2008;55:1293-9
   PubMed Web of Science ®Google Scholar
• Urwyler S. Allosteric modulation of family C G-protein-coupled receptors: from molecular insights to therapeutic perspectives. Pharmacol Rev 2011;63:59-126
   PubMed Web of Science ®Google Scholar
• Johnson MP, Baez M, Jagdmann GE, Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pirid-3-ylmethylamine. J Med Chem 2003;46:3189-92
   PubMed Web of Science ®Google Scholar
• Bonnefous C, Vernier J-M, Hutchinson JH, Biphenyl-indanones: allosteric potentiators of metabotropic glutamate subtype 2 receptor. Bioorg Med Chem Lett 2005;15:4354-8
   PubMed Web of Science ®Google Scholar
• Johnson MP, Barda D, Britton TC, Metabotropic glutamate receptor 2 potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s). Psychopharmacology (Berl) 2005;179:271-83
   PubMed Web of Science ®Google Scholar
• Galici R, Echemendia NG, Rodriguez AL, Conn JP. A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity. J Pharmacol Exp Ther 2005;315:1181-7
   PubMed Web of Science ®Google Scholar
• Galici R, Jones CK, Kamondanai H, Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice. J Pharmacol Exp Ther 2006;318:173-85
   PubMed Web of Science ®Google Scholar
• Sheffler DJ, Pinkerton AB, Dahl R, Recent progress in the synthesis and characterization of group II metabotropic glutamate receptor allosteric modulators. ACS Chem Neurosci 2011;2:382-93
   PubMed Web of Science ®Google Scholar
• Trabanco AA, Cid JM, Lavreysen H, Progress in the development of positive allosteric modulators of the metabotropic glutamate receptor 2. Curr Med Chem 2011;18:47-68
   PubMed Web of Science ®Google Scholar
• Pinkerton AB, Vernier J-M, Schaffhauser H, Phenyl-tetrazolyl acetophenones: discovery of allosteric potentiators for the metabotropic glutamate 2 receptor. J Med Chem 2004;47:4595-9
   PubMed Web of Science ®Google Scholar
• Pinkerton AB, Cube RV, Hutchinson JH, Allosteric potentiators of the metabotropic glutamate receptor 2 (mGlu2). Part 1: identification and synthesis of phenyl-tetrazolyl acetophenones. Bioorg Med Chem Lett 2004;14:5329-32
   PubMed Web of Science ®Google Scholar
• Pinkerton AB, Cube RV, Hutchinson JH, Allosteric potentiators of the metabotropic glutamate receptor 2 (mGlu2). Part 2: 4-thiopyridyl acetophenones as non-tetrazole-containing mGlu2 receptor potentiators. Bioorg Med Chem Lett 2004;14:5867-72
   PubMed Web of Science ®Google Scholar
• Cube RV, Vernier J-M, Hutchinson JH, 3-(2-ethoxy-4-{4-[3-hydroxy-2-methyl-4-(3-methylbutanoyl)phenoxy]butoxy}phenylpropanoic acid: a brain penetrant allosteric potentiator at the metabotropic glutamate receptor 2 (mGluR2). Bioorg Med Chem Lett 2005;15:2389-93
   PubMed Web of Science ®Google Scholar
• Govek SP, Bonnefous C, Hutchinson JH, Benzazoles as allosteric potentiators of metabotropic glutamate receptor 2 (mGluR2): efficacy in animal model for schizophrenia. Bioorg Med Chem Lett 2005;15:4068-72
   PubMed Web of Science ®Google Scholar
• Cid JM, Duvey G, Cluzeau P, Discovery of 1,5-disubstituted pyridines: a new class of positive allosteric modulators of the metabotropic glutamate 2 receptor. ACS Chem Neurosci 2010;1:788-95
   PubMed Web of Science ®Google Scholar
• Cid JM, Duvey G, Tresadern G, Discovery of 1,4-disubstituted 3-cyano-2-pyridones: a new class of positive allosteric modulators of the metabotropic glutamate 2 receptor. J Med Chem 2012;55:2388-405
   PubMed Web of Science ®Google Scholar
• AstraZeneca AB and NPS Pharmaceuticals, Inc. Isoindolone compounds and their use as metabotropic glutamate receptor potentiators. WO02087; 2006
   Google Scholar
• AstraZeneca AB and NPS Pharmaceuticals, Inc. Metabotropic-glutamate-receptor-potentiating isoindolones. WO021308; 2007
   Google Scholar
• AstraZeneca AB and NPS Pharmaceuticals, Inc. Pyrazolone compounds as metabotropic glutamate receptor agonists for the treatment of neurological and psychiatric disorders. WO030031; 2006
   Google Scholar
• Janssen Pharmaceuticals N.V. and Addex Pharmaceuticals S.A. Novel thieno-pyridine and thieno-pyrimidine derivatives and their use as positive allosteric modulators of mGluR2-receptors. WO030031; 2006
   Google Scholar
• Duplantier AJ, Efremov I, Candler J, 3-Benzyl-1,3-oxazolidin-2-ones as mGluR2 positive allosteric modulators: hit to lead and lead optimization. Bioorg Med Chem Lett 2009;19:2524-9
   PubMed Web of Science ®Google Scholar
• Brnardic EJ, Fraley ME, Garbaccio RM, 3-Aryl-5-phenoxymethyl-1,3-oxazolidin-2-ones as positive allosteric modulators of mGluR2 for the treatment of schizophrenia: hit-to-lead efforts. Bioorg Med Chem Lett 2010;20:3129-33
   PubMed Web of Science ®Google Scholar
• Zhang L, Rogers BN, Duplantier AJ, 3-(Imidazolyl methyl)-3-aza-bicyclo[3.1.0]hexan-6-yl)methyl ethers: a novel series of mGluR2 positive allosteric modulators. Bioorg Med Chem Lett 2008;18:5493-6
   PubMed Web of Science ®Google Scholar
• D’Alessandro PL, Corti C, Roth A, The identification of structurally novel, selective, orally bioavailable positive allosteric modulators of mGluR2. Bioorg Med Chem Lett 2010;20:759-62
   PubMed Web of Science ®Google Scholar
• Zhang L, Brodney MA, Candler J, 1-[(1-Methyl-1H-imidazol-2-yl)methyl]4-phenylpiperidines as mGluR2 positive allosteric modulators for the treatment of psychosis. J Med Chem 2011;54:1724-39
   PubMed Web of Science ®Google Scholar
• Sanofi-Aventis. Substituted dihydro and tetrahydro oxazolopyrimidones, preparation and use thereof. WO112483; 2008
   Google Scholar
• Rudd MT, McCauley JA. Positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (mGluR2). Curr Top Med Chem 2005;5:869-84
   PubMed Web of Science ®Google Scholar
• Fraley ME. Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia. Expert Opin Ther Patents 2009;1259-75
   PubMed Web of Science ®Google Scholar
• ADZ8529 single ascending dose study (SAD). ClinicalTrials.gov. Available from: http://clinicaltrials.gov/show/NCT00755378
   Google Scholar
• Study to assess the efficacy, safety, and tolerability of ADZ8529 in adult schizophrenia patients. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/show/NCT00921804
   Google Scholar
• The effects ADZ8529 on cognition and negative symptoms in schizophrenics. Available from: http://clinicaltrials.gov/show/NCT00986531
   Google Scholar
• Available from: http://www.astrazeneca.com/Investors/financial-information/Financial-results/2010-Financial-results
   Google Scholar
• Ketamine challenge study with JNJ-40411813 to investigate whether JNJ-40411813 versus placebo reduces psychosis-like symptoms, induced by infusion of a low dose of ketamine. Available from: http://clinicaltrials.gov/ct2/show/NCT01101659; ClinicalTrials.gov Identifier. NCT01101659
   Google Scholar
• Study to explore the Safety, Tolerability and Potential clinical efficacy of JNJ-40411813 in schizophrenic patients. Available from: http://clinicaltrials.gov/show/NCT01323205
   Google Scholar
• Study to evaluate the efficacy and overall safety and tolerability of treatment with adjunctive JNJ-40411813 compared to placebo in patients with MDD with anxiety symptoms being treated with an antidepressant. Available from: http://clinicaltrials.gov/show/NCT01582815
   Google Scholar
• Vinso PN, Conn JP. Metabotropic glutamate receptors as therapeutic targets for schizophrenia. Neuropharmacology 2012;62:1461-72
   PubMed Web of Science ®Google Scholar
• Hovelsø N, Sotty F, Montezinho LP, Therapeutic potential of metabotropic glutamate receptor modulators. Curr Neuropharmacol 2012;10:12-48
   PubMed Web of Science ®Google Scholar
• Abbott GmbH & Co. KG. Novel small molecule potentiators of metabotropic glutamate receptors I. US0245232; 2011
   Google Scholar
• Abbott GmbH & Co. KG. Novel small molecule potentiators of metabotropic glutamate receptors. US0245247; 2011
   Google Scholar
• AstraZeneca AB and NPS Pharmaceuticals, Inc. Isoindolone compounds and their use as metabotropic glutamate receptor potentiators. WO020879; 2006
   Google Scholar
• AstraZeneca AB. Isoxazole derivatives and their use as metabotropic glutamate receptor potentiators. WO148403; 2009
   Google Scholar
• AstraZeneca AB. Polymorphs of metabotropic glutamate receptor positive allosteric modulator. WO136723; 2011
   Google Scholar
• AstraZeneca AB. Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators. US0306077; 2008
   Google Scholar
• Eli Lilly and Co. Imidazole carboxamides. WO009062; 2010
   Google Scholar
• Fell MJ, Witkin JM, Falcone JF, N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl) benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: In vivo profiling suggests a link between behavioral and central nervous system neurochemical change. JPET 2011;336:165-77
   PubMed Web of Science ®Google Scholar
• Johnson PL, Fitz SD, Engleman EA, Group II metabotropic glutamate receptor type 2 allosteric potentiators prevent sodium lactate-induced panic-like response in panic-vulnerable rats. J Psychopharmacol 2013;27:152-61
   PubMed Web of Science ®Google Scholar
• Ortho-McNeil-Janssen Pharma, Inc. and Addex Pharmaceuticals S.A. 3-Azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors. WO025890; 2010
   Google Scholar
• Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Addex Pharma S.A. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors. WO043396; 2010
   Google Scholar
• Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Addex Pharma S.A. Imidazo[1,2-a]pyridine derivatives as positive allosteric modulators of mGluR2 receptors. WO062676; 2009
   Google Scholar
• Tresadern G, Cid J, Macdonald GJ, Scaffold hopping from pyridones to imidazo[1,2-a]pyridines. New positive allosteric modulators of metabotropic glutamate 2 receptor. Bioorg Med Chem Lett 2010;20:175-9
   PubMed Web of Science ®Google Scholar
• Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Addex Pharma S.A. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors. WO060589; 2010
   Google Scholar
• Trabanco AA, Tresadern G, Macdonald GJ, Imidazo[1,2-a]pyridines: orally active positive allosteric modulators of the metabotropic glutamate receptor 2. J Med Chem 2012;55:2688-701
   PubMed Web of Science ®Google Scholar
• Ahnaou A, Dautzenberg F, Geys H, Modulation of group II metabotropic glutamate receptor (mGlu2) elicits common changes in rat and mice sleep-wake architecture. Eur J Pharmacol 2009;603:62-72
   PubMed Web of Science ®Google Scholar
• Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Addex Pharma S.A. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors. WO130422; 2010
   Google Scholar
• Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Addex Pharma S.A. 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors. WO130423; 2010
   Google Scholar
• Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Addex Pharma S.A. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders. WO130424; 2010
   Google Scholar
• Cid JM, Tresadern G, Vega JA, Discovery of 3-cyclopropylmethyl-7-(4-phenyl-piperidin-1-yl)-8-trifluoromethyl[1,2,4]triazolo[4,3a] pyridine (JNJ-42153605): a positive allosteric modulator of the metabotropic glutamate 2 receptor. J Med Chem 2012;55:8770-89
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors. WO062750; 2012
   Google Scholar
• Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors. WO062751; 2012
   Google Scholar
• Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors. WO062759; 2012
   Google Scholar
• Janssen Pharmaceuticals, Inc. Radiolabelled mGluR2 PET ligands. WO062752; 2012
   Google Scholar
• Andres J-I, Alcazar J, Cid JM, Synthesis, evaluation, and radiolabeling of new potent positive allosteric modulators of the metabotropic glutamate receptor 2 as potential tracers for positron emission tomography imaging. J Med Chem 2012;55:8685-99
   PubMed Web of Science ®Google Scholar
• Merck & Co., Inc. 3,5-Substitured-1,3-oxazolidin-2-one derivatives. WO094265; 2009
   Google Scholar
• Merck & Co., Inc. 3,5-Substitured-1,3-oxazolidin-2-one derivatives. US0292241; 2010
   Google Scholar
• Merck & Co., Inc. Oxazolobenzimidazolone derivatives. WO140163; 2009
   Google Scholar
• Merck & Co., Inc. Oxazolobenzimidazolone derivatives. WO140166; 2009
   Google Scholar
• Garbaccio RM, Brnardic EJ, Fraley ME, Discovery of oxazolobenzimidazoles as positive allosteric modulators for the mGluR2 receptor. ACS Med Chem Lett 2010;1:406-10
   PubMed Web of Science ®Google Scholar
• Merck & Co., Inc. Benzazole potentiators of metabotropic glutamate receptors. WO091496; 2006
   Google Scholar
• Merck Sharp & Dohme Corp. Aminobenzotriazole derivatives. WO114726; 2010
   Google Scholar
• Merck Sharp & Dohme Corp. Biaryl benzotriazole derivatives. WO141360; 2010
   Google Scholar
• Merck Sharp & Dohme Corp. Ether benzotriazole derivatives. WO022312; 2011
   Google Scholar
• Merck Sharp & Dohme Corp. Ether benzotriazole derivatives. US0135977; 2012
   Google Scholar
• Merck Sharp & Dohme Corp. Aminomethyl biaryl benzotriazole derivatives. WO151136; 2012
   Google Scholar
• Merck Sharp & Dohme Corp. Hydroxymethyl biaryl benzotriazole derivatives. WO151140; 2012
   Google Scholar
• Merck Sharp & Dohme Corp. Cyclohenexe benzotriazole derivatives. WO151138; 2012
   Google Scholar
• Merck Sharp & Dohme Corp. Alkyne benzotriazole derivatives. WO151139; 2012
   Google Scholar
• Merck Sharp & Dohme Corp. Imidazopyridin-2-one derivatives. WO034741; 2011
   Google Scholar
• Merck Sharp & Dohme Corp. Positive allosteric modulators of mGluR2. WO156245; 2011
   Google Scholar
• Merck Sharp & Dohme Corp. Positive allosteric modulators of mGluR2. WO021382; 2012
   Google Scholar
• Merck Sharp & Dohme Corp. Positive allosteric modulators of mGluR2. WO109277; 2011
   Google Scholar
• Merck Sharp & Dohme Corp. Substituted 1,3-benzothiazol-2(3H)-ones and [1,3]thiazolo[5,4-b]pyridine-2(1H)-ones as positive allosteric modulators in mGluR2. WO137046; 2011
   Google Scholar
• N.V. Organon. Heterocyclic derivatives. WO051490; 2011
   Google Scholar
• Sanford-Burnham Medical Research Institute. Positive allosteric modulators of group II mGluRs. WO116356; 2011
   Google Scholar
• Dhanya R-P, Sidique S, Sheffler DJ, Design and synthesis of an orally active metabotropic glutamate receptor subtype-2 (mGluR2) positive allosteric modulator (PAM) that decreases cocaine self-administration in rats. J Med Chem 2011;54:342-53
   PubMed Web of Science ®Google Scholar
• Sidique S, Dhanya R-P, Sheffler DJ, Orally active metabotropic glutamate subtype 2 receptor positive allosteric modulators: structure-activity relationships and assessment in a rat model of nicotine dependence. J Med Chem 2012;55:9434-45
   PubMed Web of Science ®Google Scholar
• Sanofi-Aventis. Substituted dihydro, trihydro and tetrahydro cycloalkyloxazolopyrimidones, preparation and use thereof as allosteric modulators of mGluR. WO110901; 2009
   Google Scholar
• Sanofi-Aventis. Substituted para-biphenyloxymethyl dihydro oxazolopyrimidones, preparation and use thereof. WO034828; 2011
   Google Scholar
• Sanofi-Aventis. Substituted benzocycloalkyloxymethyl oxazolopyrimidones, preparation and use thereof. WO034830; 2011
   Google Scholar
• Sanofi-Aventis. Substituted phenoxymethyl dihydro oxazolopyrimidones, preparation and use thereof. WO034832; 2011
   Google Scholar
• Woolley ML, Pemberton DJ, Bate S, The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity. Psychopharmacology (Berl) 2008;196:431-40
   PubMed Web of Science ®Google Scholar
• Linden AM, Johnson BG, Trokovic N, Use of mGluR2 and mGluR3 knockout mice to explore in vivo receptor specificity of the mGluR2/3 selective agonist LY341495. Neuropharmacology 2009;57:172-82
   PubMed Web of Science ®Google Scholar
• Fell MJ, Svensson KA, Kjell A, Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulphonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039). J Pharmacol Exp Ther 2008;326:209-17
   PubMed Web of Science ®Google Scholar